Literature DB >> 23469325

Dextromethorphan and quinidine combination in emotional lability associated with depression: a case report.

Erick Messias1, Betty Everett.   

Abstract

Entities:  

Year:  2012        PMID： 23469325      PMCID： PMC3583766          DOI： 10.4088/PCC.12l01400

Source DB:  PubMed          Journal:  Prim Care Companion CNS Disord        ISSN： 2155-7780


× No keyword cloud information.
  5 in total

1.  Randomized, controlled trial of dextromethorphan/quinidine for pseudobulbar affect in multiple sclerosis.

Authors:  Hillel S Panitch; Ronald A Thisted; Richard A Smith; Daniel R Wynn; James P Wymer; Anat Achiron; Timothy L Vollmer; Raul N Mandler; Dennis W Dietrich; Malcolm Fletcher; Laura E Pope; James E Berg; Ariel Miller
Journal:  Ann Neurol       Date:  2006-05       Impact factor: 10.422

2.  A self report measure of affective lability.

Authors:  S R Moore; L S Gresham; M B Bromberg; E J Kasarkis; R A Smith
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-07       Impact factor: 10.154

3.  Treatment of pseudobulbar affect in ALS with dextromethorphan/quinidine: a randomized trial.

Authors:  B R Brooks; R A Thisted; S H Appel; W G Bradley; R K Olney; J E Berg; L E Pope; R A Smith
Journal:  Neurology       Date:  2004-10-26       Impact factor: 9.910

4.  Dextromethorphan and quinidine in adult patients with uncontrolled painful diabetic peripheral neuropathy: a 29-day, multicenter, open-label, dose-escalation study.

Authors:  Ronald A Thisted; Leslie Klaff; Sherwyn L Schwartz; James P Wymer; Neil W Culligan; Gary Gerard; Laura E Pope; James E Berg
Journal:  Clin Ther       Date:  2006-10       Impact factor: 3.393

5.  Dextromethorphan and quinidine combination for heroin detoxification.

Authors:  Evaristo Akerele; Adam Bisaga; Maria A Sullivan; Fatima Garawi; Sandra D Comer; Anil A Thomas; Edward V Nunes; Herbert D Kleber
Journal:  Am J Addict       Date:  2008 May-Jun
  5 in total
  6 in total

Review 1.  New targets for rapid antidepressant action.

Authors:  Rodrigo Machado-Vieira; Ioline D Henter; Carlos A Zarate
Journal:  Prog Neurobiol       Date:  2015-12-23       Impact factor: 11.685

Review 2.  Glutamatergic Modulators in Depression.

Authors:  Ioline D Henter; Rafael Teixeira de Sousa; Carlos A Zarate
Journal:  Harv Rev Psychiatry       Date:  2018 Nov/Dec       Impact factor: 3.732

Review 3.  Glutamate and its receptors in the pathophysiology and treatment of major depressive disorder.

Authors:  Mark J Niciu; Dawn F Ionescu; Erica M Richards; Carlos A Zarate
Journal:  J Neural Transm (Vienna)       Date:  2013-12-08       Impact factor: 3.575

Review 4.  Mood Therapeutics: Novel Pharmacological Approaches for Treating Depression.

Authors:  Ioline D Henter; Rafael T de Sousa; Philip W Gold; Andre R Brunoni; Carlos A Zarate; Rodrigo Machado-Vieira
Journal:  Expert Rev Clin Pharmacol       Date:  2017-01-16       Impact factor: 5.045

Review 5.  Therapeutic Modulation of Glutamate Receptors in Major Depressive Disorder.

Authors:  Brittany A Jaso; Mark J Niciu; Nicolas D Iadarola; Niall Lally; Erica M Richards; Minkyung Park; Elizabeth D Ballard; Allison C Nugent; Rodrigo Machado-Vieira; Carlos A Zarate
Journal:  Curr Neuropharmacol       Date:  2017       Impact factor: 7.363

Review 6.  Glutamatergic Neurotransmission: Pathway to Developing Novel Rapid-Acting Antidepressant Treatments.

Authors:  Bashkim Kadriu; Laura Musazzi; Ioline D Henter; Morgan Graves; Maurizio Popoli; Carlos A Zarate
Journal:  Int J Neuropsychopharmacol       Date:  2019-02-01       Impact factor: 5.176
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.